Hyperpolarized [2-13C] Pyruvate
Phase 1
Hyperpolarized [2-13C] Pyruvate is one of 12 therapeutic programs targeting Traumatic Brain Injury. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in Traumatic Brain Injury
#DrugCompanyPhaseTrials
1Namenda
AbbViePhase 2
Hyperbaric Oxygen Therapy
PPaul G. Harch, M.D.
Phase 2
Allorx
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
Bont-a
SSir Run Run Shaw Hospital
Phase 2
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Hyperpolarized Pyruvate
SSunnybrook Health Sciences Centre
Phase 1
OVIDREL
OOrganon and Co
Phase 1
Hyperpolarized [1-13c] Pyruvate
UUniversity of Texas Southwestern Medical Center
Phase 1
Hyperpolarized [2-13C] Pyruvate
UUniversity of Texas Southwestern Medical Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Traumatic Brain Injury1 trial
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate
Enrolling by invitation·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT03502967·60 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]